Features based on peer-reviewed papers published in Cancers.
Dr. Carmen Balana's team found that glioblastoma patients whose tumors carried the C250T TERT promoter mutation lived longer than those with the commoner C228T mutation, in a retrospective analysis.
Professor Ann-Joy Cheng's team analysed datasets to find microRNAs tied to areca nut-linked head and neck cancer, and lab tests showed one tumour-suppressing microRNA curbed cancer cell spread.
Dr. Carolina Parada's team sequenced intracranial epidermoid cysts and found recurrent NOTCH2 and USP8 mutations and immune-related changes, pointing to existing drugs that might be tested against them.
Dr. Fanny Chapelin's team used fluorine-based MRI to follow macrophages gathering in mouse breast and colon tumours after radiation, revealing different immune responses between the cancer types.
Professor Joe Hasei's team found that young people with rare cancers spoke more freely and found peer support when meeting as avatars in a virtual metaverse space.
Dr. John Michael Bryant and colleagues review how MRI-guided linear accelerators let clinicians adapt radiotherapy for brain and spine tumours to daily changes in anatomy.
Dr. Jaffer Ajani's team found that SMARCA4 mutations in gastroesophageal adenocarcinoma did not change patient survival but were linked to particular tumor subtypes, PD-L1 status and other gene mutations.
Dr. Mohammed Shahait's team reviewed evidence that diabetes drugs called GLP-1 receptor agonists may curb prostate cancer cell growth, noting that support so far comes mainly from preclinical studies.
